ClinicalTrials.gg
CompletedNCT05604885RESOLVEUpdated Nov 6, 2024

A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

A Phase 2 interventional study of AP1189, 60 mg and AP1189, 80 mg in Rheumatoid Arthritis, sponsored by SynAct Pharma Aps. Completed at 1 site in Moldova, Republic of. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by SynAct Pharma Aps · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Arthritis, Rheumatoid with a site in Moldova, Republic of — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Moldova, Republic of.

Enrollment
14th of 26
125 · median 126
Started
2022
with 1 other
Phase 2
17 of 26
none open now
Registered
25th of 26
by date
Lead sponsor
2 of 26
SynAct Pharma Aps

Among the 26 studies in Arthritis, Rheumatoid with a site in Moldova, Republic of, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 17 in phase 2, and was the 25th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 26 studies in Arthritis, Rheumatoid with a site in Moldova, Republic of is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies in Arthritis, Rheumatoid with a site in Moldova, Republic of as a file.
02

Study summary

The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult RA patients with an inadequate response to MTX alone.

Read the detailed description

In Part A approximately 120 randomized patients will be treated with either 60 mg AP1189, 80 mg AP1189, 100 mg AP1189 or placebo once daily for 4 weeks as add-on treatment to stable MTX treatment. Part A will conclude with an unblinded assessment for risk/benefit and a recommendation for dose selection for Part B.

In Part B patients will be randomized into groups of equal size evaluating 2-3 doses of AP1189 versus placebo. All doses will be administered once daily for 12 weeks as add-on treatment to stable MTX treatment. The proposed sample size per dose group/placebo group is 75 patients, by which the total study population of Part B may be either 225 or 300 patients, depending on the number of dose groups of AP1189 selected for evaluation based on Part A.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of RA according to the 2010 ACR/EULAR RA classification criteria and are ACR class I-III
  • ≥6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts)
  • Must meet at least one of the following parameters at Screening:

    1. A positive result for Anti-Cyclic Citrullinated Peptide (anti-CCP) or Rheumatoid Factor (RF),
    2. Serum CRP ≥ 6 mg/L based on central laboratory value
  • Ongoing methotrexate therapy ≥12 weeks in a stable dose of 7.5 to 25 mg/week for at least 4 weeks prior to the baseline visit
  • Subject has an inadequate clinical response to maximally tolerated methotrexate therapy
  • Subjects should be receiving an adequate and prescribed stable dose of folic acid (≥5 mg/week total dose or as per local clinical practice) which should be confirmed or initiated at screening and continued throughout the study
  • Negative QuantiFERON-in-Tube test (QFG-IT)
  • Females of must use of highly effective method
  • Male participant's partner must use highly effective birth control

Exclusion criteria

Exclusion Criteria:

  • Use of all other biologic or nonbiologic DMARDs and therapy within 4 weeks prior to administration of the first dose of study drug
  • Oral at a dose >10 mg/day of prednisone or a prescription for oral steroids which has changed within 4 weeks of baseline
  • Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks prior to baseline
  • Major surgery (including joint operation) within 8 weeks prior to screening or planned surgery within the period of the study participation
  • Rheumatic disease other than RA
  • Functional class IV as defined by the ACR Criteria for Classification of Functional Status in RA or wheelchair/bedbound
  • Prior history of or current inflammatory joint disease other than RA
  • Subjects with fibromyalgia
  • Initiation or change in dose for NSAIDs (including low-dose aspirin and Cyclooxygenase (COX-2) inhibitors) within 2 weeks prior to baseline
  • Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
  • Serum (ALT) and/or aspartate aminotransferase (AST) higher than 1.5 x the (ULN) and alkaline phosphatase (ALP) and/or values above the ULN at the screening visit
  • Have prior renal transplant, current renal dialysis, or moderate to severe renal insufficiency
  • Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
  • Evidence of active malignant disease (except basal cell carcinoma of the skin that has been excised and cured)
  • History of alcohol, drug, or chemical abuse within the 6 months prior to screening
  • Neuropathy or other painful, chronic conditions that might interfere with pain evaluation
  • Body weight of >150 kg
  • positive and/or Anti-HBc with sign of current infection.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    AP1189, 60 mg

    Part A: (AP1189, 60 mg); Part B: (TBD)

    Drug: AP1189, 60 mg

  • Experimental
    AP1189, 80 mg

    Part A: (AP1189, 80 mg); Part B: (TBD)

    Drug: AP1189, 80 mg

  • Experimental
    AP1189, 100 mg

    Part A: (AP1189, 100 mg); Part B: (TBD)

    Drug: AP1189, 100 mg

  • Placebo comparator
    Placebo

    Part A: (placebo); Part B: (placebo).

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Change in ACR20

    The change in American College of Rheumatology 20% (ACR20) compared to baseline

    Time frame: 4 weeks

  2. Part B: Change in ACR20

    The change in American College of Rheumatology 20% (ACR20) compared to baseline

    Time frame: 12 weeks

  3. Number of reported Adverse Events

    Evaluation of the safety and tolerability of AP1189 on the number and severity of reported Adverse Events, compared with placebo

    Time frame: 12 weeks

Secondary outcomes

  1. Part A: Change in ACR50

    The change in American College of Rheumatology 50% (ACR50) compared to baseline

    Time frame: 4 weeks

  2. Part B: Change in ACR50

    The change in American College of Rheumatology 50% (ACR50) compared to baseline

    Time frame: 12 weeks

  3. Part A: Change in ACR70

    The change in American College of Rheumatology 70% (ACR70) compared to baseline

    Time frame: 4 weeks

  4. Part B: Change in ACR70

    The change in American College of Rheumatology 70% (ACR70) compared to baseline

    Time frame: 12 weeks

  5. Part A: Change in CDAI

    The change Clinical Disease Activity Index (CDAI) compared to baseline

    Time frame: 4 weeks

  6. Part B: Change in CDAI

    The change Clinical Disease Activity Index (CDAI) compared to baseline

    Time frame: 12 weeks

  7. Part A: Change in DAS-28

    The change in Disease Activity Score (DAS-28), based on a C-Reactive Protein (CRP) value, compare to baseline

    Time frame: 4 weeks

  8. Part B: Change in DAS-28

    The change in Disease Activity Score (DAS-28), based on a C-Reactive Protein (CRP) value, compare to baseline

    Time frame: 12 weeks

07

Study locations

1 site
  • Timofei Mosneaga Republican Clinical Hospital
    Chișinău, Moldova, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2023, 8 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 8 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2022
First posted
Nov 3, 2022
StartActual
Nov 30, 2022
Primary completionActual
Aug 28, 2023
CompletionActual
Aug 28, 2023
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05604885
Lead sponsor
SynAct Pharma Aps
Collaborators
NBCD A/S
Responsible party
Sponsor
First posted
Nov 3, 2022
Start date
Nov 30, 2022
Primary completion
Aug 28, 2023
Completion
Aug 28, 2023
Last update
Nov 6, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resomelagon acetate

Start the discussion